Company Cell Source Inc OTC Bulletin Board

Equities

US15114L1044

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Mar. 22	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
2023	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Managers	Title	Age	Since
Itamar Shimrat CEO	Chief Executive Officer	63	-

Members of the board	Title	Age	Since
Dennis Brown CHM	Chairman	74	14-06-29
Itamar Shimrat CEO	Chief Executive Officer	63	-
Darlene Soave BRD	Director/Board Member	80	21-03-24
George Verstraete BRD	Director/Board Member	-	22-03-09

	Vote	Quantity	Free-Float	Total Float
Stock A	0	532,110	0	70.08 %
Stock B	1	38,546,231	27,015,038 ( 70.08 %)
Stock C	0	1,261,749	0

Name	Equities	%	Valuation
Ben Friedman 11.85 %	4,569,044	11.85 %	1 M $
Weizmann Institute of Science 8.186 %	3,155,348	8.186 %	981 313 $
George Verstraete 6.161 %	2,375,000	6.161 %	738 625 $
Hua Tuo Online Ltd. 1.588 %	612,265	1.588 %	190 414 $
Igea Brain, Spine & Orthopedics 1.588 %	612,265	1.588 %	190 414 $
Acuity Investments LLC 1.536 %	591,911	1.536 %	184 084 $
Itamar Shimrat 1.492 %	575,004	1.492 %	178 826 $
Darlene Soave 1.447 %	557,923	1.447 %	173 514 $
Mario Dellarea 0.8030 %	309,543	0.8030 %	96 268 $
Ingram Tynes 0.3800 %	146,465	0.3800 %	45 551 $

Name	Equities	%	Valuation
digiMine LLC -	61,296	-	19 063 $
Ingram Tynes -	40,000	-	12 440 $
Susan Mccracken -	33,333	-	10 367 $
Steven Tenenbaum -	26,667	-	8 293 $
Paul Woodward -	26,666	-	8 293 $

Name	Equities	%	Valuation
Darlene Soave -	133,334	-	41 467 $
Hua Tuo Online Ltd. -	133,334	-	41 467 $
Acuity Investments LLC -	130,402	-	40 555 $
Igea Brain, Spine & Orthopedics -	108,667	-	33 795 $
Mario Dellarea -	76,500	-	23 792 $
Ben Friedman -	43,553	-	13 545 $
Ingram Tynes -	23,330	-	7 256 $
Dennis Brown -	6,667	-	2 073 $

Cell Source, Inc.

57 West 57th Street Suite 400

10019, New York

http://www.cell-source.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs